UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
____________________________________________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
___________________________________________________________________
Date
of
Report (Date of earliest event reported): November
3, 2008
|
Transdel
Pharmaceuticals, Inc.
|
||
|
(Exact
name of registrant as specified in its charter)
|
||
|
Delaware
|
000-52998
|
45-0567010
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
4225
Executive Square, Suite 485
La
Jolla, CA
|
92037
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
|
Registrant’s
telephone number, including area code: (858)
457-5300
|
||
|
N/A
|
||
|
(Former
name or former address, if changed since last
report)
|
||
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
In
September 2008, Transdel Pharmaceuticals, Inc. (the “Company”) announced that
the first patient had been enrolled in its Phase 3 clinical trial for
Ketotransdel™. The clinical trial is well underway and is being executed by Cato
Research Ltd. With the Company’s Phase 3 clinical trial moving from the planning
and development stage to the execution stage, the Company and Paul Finnegan,
M.D., M.B.A., F.R.C.P.C., have agreed that Dr. Finnegan will transition from
the
Company’s Chief Medical Officer and Chief Operating Officer to a consultant of
the Company. The effective date of Dr. Finnegan’s transition will be November
17, 2008. Dr. Finnegan’s transition from a full time employee and officer of the
Company to a consultant did not result from any disagreement between Dr.
Finnegan and the Company or its Board of Directors. The Company and
Dr. Finnegan are currently negotiating the terms of his consulting
agreement with the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Transdel
Pharmaceuticals, Inc.
|
||
| |
|
|
|
Date:
November 7, 2008
|
By: | /s/ John T. Lomoro |
|
John
T. Lomoro
|
||
|
Chief
Financial Officer
|
||